Snapshot from Jul 19, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / Oxford develops statin risk calculator
Tech medical breakthrough

Oxford develops statin risk calculator

Analysis based on 7 articles · First reported Jun 25, 2026 · Last updated Jul 08, 2026

Sentiment
60
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The development of this calculator by the University of Oxford could increase statin prescription rates, positively impacting pharmaceutical companies that produce statins. It may also lead to more informed patient decisions, potentially reducing healthcare costs associated with cardiovascular diseases.

pharmaceuticals healthcare
Event Summary

Researchers at the University of Oxford's Nuffield Department of Primary Care Health Sciences have developed a new risk calculator to estimate an individual's risk of serious muscle disorders from statins. Published in The Lancet Digital Health, the study, led by Ting Cai, James Sheppard, and Constantinos Kombos, found that over 98% of statin-eligible individuals have a low risk of serious muscle problems. The tool, available via Oxford University Innovation, uses 22 factors from patient records to provide personalized risk estimates, aiming to address patient concerns about side effects and encourage more informed decisions about statin therapy, especially given that over 60% of eligible patients are not currently taking statins.

Key Actions
60 The Lancet Digital Health published research
Entities Involved
per
Ting Cai
Ting Cai is the lead author of the study, playing a crucial role in the development and communication of the statin risk calculator's findings.
Importance 80.0 Sentiment 60.0
per
James Sheppard
James Sheppard is a senior author of the study, contributing to the research and its implications for personalized statin treatment.
Importance 70.0 Sentiment 60.0
per
Constantinos Kombos
Constantinos Kombos is a senior author of the study, providing expertise in medical statistics for the development of the risk model.
Importance 70.0 Sentiment 60.0
oth
The Lancet Digital Health
The Lancet Digital Health published the research behind the new statin risk calculator, giving the study credibility and wider dissemination.
Importance 60.0 Sentiment 50.0
priv
Oxford University Innovation
Oxford University Innovation is the platform through which the new statin risk calculator is available, facilitating its practical application.
Importance 40.0 Sentiment 50.0
oth
University of Nicosia Medical School
The University of Nicosia Medical School is affiliated with Constantinos Kombos, a senior author of the study, contributing to the research.
Importance 30.0 Sentiment 50.0
oth
QRISK
QRISK is an existing cardiovascular risk assessment tool that the new statin risk calculator is designed to be used alongside, enhancing comprehensive patient evaluation.
Importance 30.0 Sentiment 40.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.